Google
CLGN Stock Price & Analysis — Collplant Biotechnologies LTD (Healthcare >> Biotechnology)
CLGN FAQ
What is CLGN's ROE?
Collplant Biotechnologies LTD reports a Return on Equity (ROE) of -268.81%.
What is CLGN's dividend yield?
Collplant Biotechnologies LTD offers a dividend yield of 0.00%.
What is CLGN's Quality Score?
Our AI rates CLGN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CLGN?
Our AI Timing Score for CLGN is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CLGN belong to?
Collplant Biotechnologies LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CLGN AI Analysis Summary
Our AI summary for CLGN: Collplant Biotechnologies LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -268.81%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.29
Price
0.02
(8.12%)
Day Change
|
|
|---|
CLGN, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.29 |
| PBV / Sector |
1.23 / 44,022.72
GOOD
|
| Earning Per Share | -0.63 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
6946.057770000000
|
| Average 1W Daily Value |
0.01 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 07:59:59 |
| Symbol | CLGN |
| Name | COLLPLANT BIOTECHNOLOGIES LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 18.91 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6.01 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Weizmann Science Park, Rehovot, Israel, 7670104
Phone: 972 73 232 5600
Website: https://collplant.com
Sector: Healthcare >> Biotechnology
Description: CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap